Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model
- 1 January 2000
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 7 (1), 43-52
- https://doi.org/10.1038/sj.gt.3301054
Abstract
To develop a cellular vehicle able to reach systemically disseminated areas of angiogenesis, we sought to exploit the natural tropism of circulating endothelial progenitor cells (EPCs). Primate CD34+ EPCs were genetically modified with high efficiency and minimal toxicity using a non-replicative herpes virus vector. These EPCs localized in a skin autograft model of angiogenesis in rhesus monkeys, and sustained the expression of a reporter gene for several weeks while circulating in the blood. In animals infused with autologous CD34+ EPCs transduced with a thymidine kinase-encoding herpes virus, skin autografts and subcutaneous Matrigel pellets impregnated with vascular growth factors underwent necrosis or accelerated regression after administration of ganciclovir. Importantly, the whole intervention was perfectly well tolerated. The accessibility, easy manipulation, lack of immunogenicity of the autologous CD34+ cell vehicles, and tropism for areas of angiogenesis render autologous CD34+ circulating endothelial progenitors as ideal candidates for exploration of their use as cellular vehicles when systemic gene delivery to those areas is required. Gene Therapy (2000) 7, 43-52.Keywords
This publication has 39 references indexed in Scilit:
- Cellular immune response to adenoviral vector infected cells does not requirede novoviral gene expression: Implications for gene therapyProceedings of the National Academy of Sciences, 1998
- Antiangiogenic gene therapyProceedings of the National Academy of Sciences, 1998
- Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice.Journal of Clinical Investigation, 1998
- A triploblast origin for Myxozoa?Nature, 1998
- Gene therapy strategies for tumor antiangiogenesisJNCI Journal of the National Cancer Institute, 1998
- Gene therapyProceedings of the National Academy of Sciences, 1997
- Mesothelial Cells: The Panacea for Ex Vivo Gene Therapy? The First Physiologically Regulated Transgene for Gene Therapy: ErythropoietinHuman Gene Therapy, 1997
- Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors FollowingIn VivoAdministrationHuman Gene Therapy, 1997
- Gene therapy in transplantationTransplant Immunology, 1996
- Method for Multiple Portal Vein Infusions in Mice: Quantitation of Adenovirus-Mediated Hepatic Gene TransferBioTechniques, 1996